This year has seen sharp stock moves as companies report financial results and update investors on early and mid-stage drug studies ...

Some of the world's largest hedge funds are hiring doctors, scientists and analysts to give them expert insight into the ...

Bristol Myers Squibb Co. closed $2.39 below its 52-week high ($61.08), which the company reached on November 11th.

Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...

RWJBarnabas Health appoints Steven Stylianos, MD as system director for pediatric surgery and surgeon-in-chief at Bristol-Myers Squibb Children's Hospital ...

Progression-free survival was improved among patients who received nivolumab and ipilimumab, and toxicity was generally greater among patients who received chemotherapy.

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Keros and Takeda on Tuesday said the deal gives Takeda an exclusive license to further develop, manufacture and commercialize elritercept outside of mainland China, Hong Kong and Macau in exchange for ...

Bristol Myers Squibb became the latest large drugmaker to sue the federal government over a plan to change how it doles out ...

Bristol Myers Squibb has enlisted three-year-old Massachusetts biotech AI Proteins to use its artificial intelligence-driven ...

We recently published a list of 10 Stocks That Are Close To Becoming Dividend Aristocrats. In this article, we are going to ...